Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
CARMEL, Ind. - MBX Biosciences , Inc. (NASDAQ:MBX) reported fourth quarter earnings on Sunday, with shares rising 5% in response to positive updates on the company’s clinical pipeline.
The clinical-stage biopharmaceutical company, focused on developing novel peptide therapies for endocrine and metabolic disorders, reported a Q4 adjusted loss of -$0.47 per share. While no analyst estimates were provided for comparison, MBX highlighted several key developments across its drug candidates.
MBX announced the completion of enrollment for its Phase 2 Avail trial of canvuparatide in hypoparathyroidism patients, with topline results expected in Q3 2025. The company also plans to initiate a Phase 2 trial of MBX 1416 for post-bariatric hypoglycemia in the second half of 2025, following positive Phase 1 results.
Additionally, MBX is on track to submit an Investigational New Drug application in Q2 2025 for MBX 4291, its obesity treatment candidate.
"MBX is entering 2025 with strong momentum following significant and transformational progress in 2024," said Kent Hawryluk, President and CEO of MBX Biosciences.
The company reported cash, cash equivalents and marketable securities of $262.1 million as of December 31, 2024, which it expects will fund operations into mid-2027.
Research and development expenses for Q4 2024 increased to $15.2 million, up from $7.7 million in Q4 2023, driven by ongoing clinical trials and IND-enabling studies. Full-year R&D expenses rose to $57.4 million from $28.5 million YoY.
MBX’s net loss for Q4 2024 widened to $15.6 million, compared to a net loss of $8.8 million in the same period last year. The full-year 2024 net loss increased to $61.9 million from $32.6 million in 2023.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.